Neglected Tropical Disease News and Research

RSS
Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

Tentative FDA approval of lopinavir/ritonavir oral pellet formulation closes treatment gap for children with HIV

New ground-breaking initiative aims to find new treatments for leishmaniasis and Chagas disease

New ground-breaking initiative aims to find new treatments for leishmaniasis and Chagas disease

GHIT Fund expands investments in leishmaniasis, diagnostic tests

GHIT Fund expands investments in leishmaniasis, diagnostic tests

Researchers identify three genes involved in choroid plexus carcinoma

Researchers identify three genes involved in choroid plexus carcinoma

Papers on antibiotic resistance, neglected diseases and future of the ocean to be discussed during G7 summit

Papers on antibiotic resistance, neglected diseases and future of the ocean to be discussed during G7 summit

Study explores artemisinin resistance in Plasmodium falciparum malaria

Study explores artemisinin resistance in Plasmodium falciparum malaria

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

Novel financing technique may unlock funding for developing 'orphan' drugs to treat rare diseases

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

MPP, MSD sign licensing agreement for paediatric formulations of raltegravir

QDREC software may help find effective treatment for schistosomiasis

QDREC software may help find effective treatment for schistosomiasis

R. Geigy Foundation recognizes scientific endeavours in neglected disease research, public health

R. Geigy Foundation recognizes scientific endeavours in neglected disease research, public health

DNDi awarded USAID grant to develop new treatments for river blindness, elephantiasis

DNDi awarded USAID grant to develop new treatments for river blindness, elephantiasis

ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

ANTRUK welcomes first report on antibiotic resistance; becomes BIA’s 2015 charity

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Bayer, DNDi sign first agreement to develop new oral treatment for onchocerciasis

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Monash University, 60P Australia partner to develop Fenretinide drug for dengue fever

Gates Foundation provides $2 million grant to help fight major parasitic diseases

Gates Foundation provides $2 million grant to help fight major parasitic diseases

Research breakthroughs may pave way for new drugs to fight against parasitic worm infections

Research breakthroughs may pave way for new drugs to fight against parasitic worm infections

Treeway, LACDR join forces to optimize clinical trial designs, data-analysis for ALS

Treeway, LACDR join forces to optimize clinical trial designs, data-analysis for ALS

AfriCoLeish launches Phase III clinical study to test 2 treatments for HIV-VL co-infected patients

AfriCoLeish launches Phase III clinical study to test 2 treatments for HIV-VL co-infected patients

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Celgene Global Health, DNDi expand partnership to identify new drug candidates for NTDs

Researchers to develop global database on situation and evolution of Chagas disease

Researchers to develop global database on situation and evolution of Chagas disease

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.